Geron Corporation (GERN) - Latest Market Data

Price & Market Data

Price: $1.28

Daily Change: +$0.02 / 1.56%

Daily Range: $1.25 - $1.29

Market Cap: $821,146,816

Daily Volume: 6,867,345

Performance Metrics

1 Week: -9.29%

1 Month: -16.99%

3 Months: -33.16%

6 Months: 17.59%

1 Year: -3.05%

YTD: -4.51%

About Geron Corporation (GERN)

Dive into the latest financial snapshot of Geron Corporation (GERN). With a current trading price of 1.28, the stock has experienced a daily shift of +$0.02 / 1.56%. The company's market capitalization stands impressively at 821,146,816. Track its year-to-date performance, which is at -4.51%, alongside its weekly, monthly, and yearly trends.

Company Details

Employees: 258

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Selected stocks

Empire Petroleum Corporation (EP)

AN2 Therapeutics, Inc. (ANTX)

Vivani Medical, Inc. (VANI)

Delixy Holdings Limited (DLXY)

IGC Pharma, Inc. (IGC)